Shoreline Biosciences, Inc. and BeiGene, Ltd. announced a worldwide collaboration to develop and commercialize a portfolio of natural killer (NK)-based cell therapeutics with Shoreline’s iPSC NK cell technology and BeiGene’s research and clinical development capabilities for different malignancies.
[nan]
Sorry, but the selected Zotpress account can't be found.
